Top Markets
#1 Velas Velas +480.91%
#2 Siren Siren +109.58%
#3 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#4 Venom Venom +45.46%
#5 Gigachad Gigachad +23.69%
#6 Ontology Ontology +20.18%
#7 Scor Scor +17.06%
#8 Dacxi Dacxi +16.49%
#9 Strategic Oil Supply Strategic Oil Supply +15.04%
#10 TRIA TRIA +14.71%
Coin of the day
Velas Velas
Cài đặt
Ngôn ngữ
TIếNG VIệT
Tiền tệ
USD
Chủ đề
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Xếp hạng trong cổ phiếu #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Giá cổ phiếu
$0.0416118
Vốn hóa thị trường
$12.78M
Thay đổi (1 ngày)
1.72%
Thay đổi (1 năm)
-22.01%
Quốc gia
AU
Giao dịch Noxopharm Limited (NOX)

Danh mục

Healthcare
Doanh thu của Noxopharm Limited (NOX)
Doanh thu vào Dec 2025 TTM: $1.11M
Theo các báo cáo tài chính gần đây của Noxopharm Limited, doanh thu hiện tại của công ty (TTM) là $1.11M. Trong năm 2024, công ty đạt doanh thu $1.60M giảm so với doanh thu năm 2023, là $4.00M. Doanh thu là tổng số tiền công ty tạo ra từ việc bán hàng hóa hoặc dịch vụ. Không giống như lợi nhuận, doanh thu không trừ chi phí.
Lịch sử doanh thu của Noxopharm Limited từ 2016 đến 2026
Doanh thu vào cuối mỗi năm
Năm Doanh thu Thay đổi
2026 (TTM) $1.11M -40.21%
2025 $1.86M 15.87%
2024 $1.60M -59.98%
2023 $4.00M 6.95%
2022 $3.74M -10.96%
2021 $4.21M -26.42%
2020 $5.71M 116.95%
2019 $2.63M 288.04%
2018 $678.81K 597.95%
2017 $97.26K 0.00%
2016 0.00 0.00%
Doanh thu của các công ty hoặc đối thủ tương tự
Công ty Doanh thu Chênh lệch doanh thu Quốc gia
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 4,362,149.84%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 1,084,093.51%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 1,291,639.69%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 817,860.65%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 1,413,432.75%
AU